ID   HSP82_YEAST             Reviewed;         709 AA.
AC   P02829; D6W3D1;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   28-JAN-2026, entry version 253.
DE   RecName: Full=ATP-dependent molecular chaperone HSP82;
DE   AltName: Full=82 kDa heat shock protein;
DE   AltName: Full=Heat shock protein Hsp90 heat-inducible isoform;
GN   Name=HSP82; Synonyms=HSP90; OrderedLocusNames=YPL240C;
OS   Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes;
OC   Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=559292;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=6325446; DOI=10.1016/s0021-9258(18)91077-x;
RA   Farrelly F.W., Finkelstein D.B.;
RT   "Complete sequence of the heat shock-inducible HSP90 gene of Saccharomyces
RT   cerevisiae.";
RL   J. Biol. Chem. 259:5745-5751(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=9169875; DOI=10.1038/387s103;
RA   Bussey H., Storms R.K., Ahmed A., Albermann K., Allen E., Ansorge W.,
RA   Araujo R., Aparicio A., Barrell B.G., Badcock K., Benes V., Botstein D.,
RA   Bowman S., Brueckner M., Carpenter J., Cherry J.M., Chung E.,
RA   Churcher C.M., Coster F., Davis K., Davis R.W., Dietrich F.S., Delius H.,
RA   DiPaolo T., Dubois E., Duesterhoeft A., Duncan M., Floeth M., Fortin N.,
RA   Friesen J.D., Fritz C., Goffeau A., Hall J., Hebling U., Heumann K.,
RA   Hilbert H., Hillier L.W., Hunicke-Smith S., Hyman R.W., Johnston M.,
RA   Kalman S., Kleine K., Komp C., Kurdi O., Lashkari D., Lew H., Lin A.,
RA   Lin D., Louis E.J., Marathe R., Messenguy F., Mewes H.-W., Mirtipati S.,
RA   Moestl D., Mueller-Auer S., Namath A., Nentwich U., Oefner P., Pearson D.,
RA   Petel F.X., Pohl T.M., Purnelle B., Rajandream M.A., Rechmann S.,
RA   Rieger M., Riles L., Roberts D., Schaefer M., Scharfe M., Scherens B.,
RA   Schramm S., Schroeder M., Sdicu A.-M., Tettelin H., Urrestarazu L.A.,
RA   Ushinsky S., Vierendeels F., Vissers S., Voss H., Walsh S.V., Wambutt R.,
RA   Wang Y., Wedler E., Wedler H., Winnett E., Zhong W.-W., Zollner A.,
RA   Vo D.H., Hani J.;
RT   "The nucleotide sequence of Saccharomyces cerevisiae chromosome XVI.";
RL   Nature 387:103-105(1997).
RN   [3]
RP   GENOME REANNOTATION.
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=24374639; DOI=10.1534/g3.113.008995;
RA   Engel S.R., Dietrich F.S., Fisk D.G., Binkley G., Balakrishnan R.,
RA   Costanzo M.C., Dwight S.S., Hitz B.C., Karra K., Nash R.S., Weng S.,
RA   Wong E.D., Lloyd P., Skrzypek M.S., Miyasato S.R., Simison M., Cherry J.M.;
RT   "The reference genome sequence of Saccharomyces cerevisiae: Then and now.";
RL   G3 (Bethesda) 4:389-398(2014).
RN   [4]
RP   INDUCTION.
RX   PubMed=2674684; DOI=10.1128/mcb.9.9.3919-3930.1989;
RA   Borkovich K.A., Farrelly F.W., Finkelstein D.B., Taulien J., Lindquist S.;
RT   "hsp82 is an essential protein that is required in higher concentrations
RT   for growth of cells at higher temperatures.";
RL   Mol. Cell. Biol. 9:3919-3930(1989).
RN   [5]
RP   ATPASE ACTIVITY.
RX   PubMed=8419347; DOI=10.1016/s0021-9258(18)54100-4;
RA   Nadeau K., Das A., Walsh C.T.;
RT   "Hsp90 chaperonins possess ATPase activity and bind heat shock
RT   transcription factors and peptidyl prolyl isomerases.";
RL   J. Biol. Chem. 268:1479-1487(1993).
RN   [6]
RP   MUTAGENESIS OF GLY-313; GLU-431; THR-525; ALA-576 AND ARG-579.
RX   PubMed=8248264; DOI=10.1073/pnas.90.23.11424;
RA   Bohen S.P., Yamamoto K.R.;
RT   "Isolation of Hsp90 mutants by screening for decreased steroid receptor
RT   function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:11424-11428(1993).
RN   [7]
RP   INTERACTION WITH STI1 AND CPR6.
RX   PubMed=7929182; DOI=10.1016/s0021-9258(17)31486-2;
RA   Chang H.-C.J., Lindquist S.;
RT   "Conservation of Hsp90 macromolecular complexes in Saccharomyces
RT   cerevisiae.";
RL   J. Biol. Chem. 269:24983-24988(1994).
RN   [8]
RP   MUTAGENESIS OF THR-22; ALA-41; GLY-81; THR-101; GLY-170; GLY-313; GLU-381
RP   AND ALA-587.
RX   PubMed=7791797; DOI=10.1128/mcb.15.7.3917;
RA   Nathan D.F., Lindquist S.;
RT   "Mutational analysis of Hsp90 function: interactions with a steroid
RT   receptor and a protein kinase.";
RL   Mol. Cell. Biol. 15:3917-3925(1995).
RN   [9]
RP   INTERACTION WITH CPR6 AND CPR7.
RX   PubMed=8939862; DOI=10.1126/science.274.5293.1713;
RA   Duina A.A., Chang H.-C.J., Marsh J.A., Lindquist S., Gaber R.F.;
RT   "A cyclophilin function in Hsp90-dependent signal transduction.";
RL   Science 274:1713-1715(1996).
RN   [10]
RP   INDUCTION.
RX   PubMed=9296388; DOI=10.1242/jcs.110.16.1879;
RA   Zarzov P., Boucherie H., Mann C.;
RT   "A yeast heat shock transcription factor (Hsf1) mutant is defective in both
RT   Hsc82/Hsp82 synthesis and spindle pole body duplication.";
RL   J. Cell Sci. 110:1879-1891(1997).
RN   [11]
RP   INTERACTION WITH SBA1.
RX   PubMed=9817749; DOI=10.1083/jcb.143.4.901;
RA   Obermann W.M., Sondermann H., Russo A.A., Pavletich N.P., Hartl F.U.;
RT   "In vivo function of Hsp90 is dependent on ATP binding and ATP
RT   hydrolysis.";
RL   J. Cell Biol. 143:901-910(1998).
RN   [12]
RP   INTERACTION WITH SBA1, AND MUTAGENESIS OF ALA-97 AND SER-485.
RX   PubMed=9632755; DOI=10.1128/mcb.18.7.3727;
RA   Fang Y., Fliss A.E., Rao J., Caplan A.J.;
RT   "SBA1 encodes a yeast hsp90 cochaperone that is homologous to vertebrate
RT   p23 proteins.";
RL   Mol. Cell. Biol. 18:3727-3734(1998).
RN   [13]
RP   INTERACTION WITH HAP1.
RX   PubMed=9632766; DOI=10.1128/mcb.18.7.3819;
RA   Zhang L., Hach A., Wang C.;
RT   "Molecular mechanism governing heme signaling in yeast: a higher-order
RT   complex mediates heme regulation of the transcriptional activator HAP1.";
RL   Mol. Cell. Biol. 18:3819-3828(1998).
RN   [14]
RP   INTERACTION WITH CNS1.
RX   PubMed=9819421; DOI=10.1128/mcb.18.12.7344;
RA   Dolinski K.J., Cardenas M.E., Heitman J.;
RT   "CNS1 encodes an essential p60/Sti1 homolog in Saccharomyces cerevisiae
RT   that suppresses cyclophilin 40 mutations and interacts with Hsp90.";
RL   Mol. Cell. Biol. 18:7344-7352(1998).
RN   [15]
RP   INTERACTION WITH SSE1.
RX   PubMed=10480867; DOI=10.1074/jbc.274.38.26654;
RA   Liu X.-D., Morano K.A., Thiele D.J.;
RT   "The yeast Hsp110 family member, Sse1, is an Hsp90 cochaperone.";
RL   J. Biol. Chem. 274:26654-26660(1999).
RN   [16]
RP   INTERACTION WITH GCN2.
RX   PubMed=10567567; DOI=10.1128/mcb.19.12.8422;
RA   Donze O., Picard D.;
RT   "Hsp90 binds and regulates Gcn2, the ligand-inducible kinase of the alpha
RT   subunit of eukaryotic translation initiation factor 2.";
RL   Mol. Cell. Biol. 19:8422-8432(1999).
RN   [17]
RP   BINDING TO TPR REPEATS.
RX   PubMed=10786835; DOI=10.1016/s0092-8674(00)80830-2;
RA   Scheufler C., Brinker A., Bourenkov G., Pegoraro S., Moroder L.,
RA   Bartunik H., Hartl F.U., Moarefi I.;
RT   "Structure of TPR domain-peptide complexes: critical elements in the
RT   assembly of the Hsp70-Hsp90 multichaperone machine.";
RL   Cell 101:199-210(2000).
RN   [18]
RP   ATPASE ACTIVITY, AND MUTAGENESIS OF ALA-107.
RX   PubMed=10944121; DOI=10.1093/emboj/19.16.4383;
RA   Prodromou C., Panaretou B., Chohan S., Siligardi G., O'Brien R.,
RA   Ladbury J.E., Roe S.M., Piper P.W., Pearl L.H.;
RT   "The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient
RT   dimerization of the N-terminal domains.";
RL   EMBO J. 19:4383-4392(2000).
RN   [19]
RP   INTERACTION WITH CDC37 AND STE11.
RX   PubMed=10664467; DOI=10.1016/s0014-5793(00)01134-0;
RA   Abbas-Terki T., Donze O., Picard D.;
RT   "The molecular chaperone Cdc37 is required for Ste11 function and
RT   pheromone-induced cell cycle arrest.";
RL   FEBS Lett. 467:111-116(2000).
RN   [20]
RP   INTERACTION WITH AHA1 AND HCH1.
RX   PubMed=12504007; DOI=10.1016/s1097-2765(02)00785-2;
RA   Panaretou B., Siligardi G., Meyer P., Maloney A., Sullivan J.K., Singh S.,
RA   Millson S.H., Clarke P.A., Naaby-Hansen S., Stein R., Cramer R.,
RA   Mollapour M., Workman P., Piper P.W., Pearl L.H., Prodromou C.;
RT   "Activation of the ATPase activity of hsp90 by the stress-regulated
RT   cochaperone aha1.";
RL   Mol. Cell 10:1307-1318(2002).
RN   [21]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=14562095; DOI=10.1038/nature02026;
RA   Huh W.-K., Falvo J.V., Gerke L.C., Carroll A.S., Howson R.W.,
RA   Weissman J.S., O'Shea E.K.;
RT   "Global analysis of protein localization in budding yeast.";
RL   Nature 425:686-691(2003).
RN   [22]
RP   LEVEL OF PROTEIN EXPRESSION [LARGE SCALE ANALYSIS].
RX   PubMed=14562106; DOI=10.1038/nature02046;
RA   Ghaemmaghami S., Huh W.-K., Bower K., Howson R.W., Belle A., Dephoure N.,
RA   O'Shea E.K., Weissman J.S.;
RT   "Global analysis of protein expression in yeast.";
RL   Nature 425:737-741(2003).
RN   [23]
RP   MUTAGENESIS OF GLY-83.
RX   PubMed=18256191; DOI=10.1242/dev.018150;
RA   Hawkins T.A., Haramis A.P., Etard C., Prodromou C., Vaughan C.K.,
RA   Ashworth R., Ray S., Behra M., Holder N., Talbot W.S., Pearl L.H.,
RA   Strahle U., Wilson S.W.;
RT   "The ATPase-dependent chaperoning activity of Hsp90a regulates thick
RT   filament formation and integration during skeletal muscle
RT   myofibrillogenesis.";
RL   Development 135:1147-1156(2008).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18407956; DOI=10.1074/mcp.m700468-mcp200;
RA   Albuquerque C.P., Smolka M.B., Payne S.H., Bafna V., Eng J., Zhou H.;
RT   "A multidimensional chromatography technology for in-depth phosphoproteome
RT   analysis.";
RL   Mol. Cell. Proteomics 7:1389-1396(2008).
RN   [25] {ECO:0007744|PDB:1AH6, ECO:0007744|PDB:1AH8}
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   PubMed=9187656; DOI=10.1038/nsb0697-477;
RA   Prodromou C., Roe S.M., Piper P.W., Pearl L.H.;
RT   "A molecular clamp in the crystal structure of the N-terminal domain of the
RT   yeast Hsp90 chaperone.";
RL   Nat. Struct. Biol. 4:477-482(1997).
RN   [26] {ECO:0007744|PDB:1A4H, ECO:0007744|PDB:1AM1, ECO:0007744|PDB:1AMW}
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 2-214 IN COMPLEX WITH ADP AND
RP   GELDANAMYCIN.
RX   PubMed=9230303; DOI=10.1016/s0092-8674(00)80314-1;
RA   Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H.;
RT   "Identification and structural characterization of the ATP/ADP-binding site
RT   in the Hsp90 molecular chaperone.";
RL   Cell 90:65-75(1997).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 273-560, AND MUTAGENESIS OF
RP   PHE-349; ARG-380 AND GLN-384.
RX   PubMed=12667448; DOI=10.1016/s1097-2765(03)00065-0;
RA   Meyer P., Prodromou C., Hu B., Vaughan C.K., Roe S.M., Panaretou B.,
RA   Piper P.W., Pearl L.H.;
RT   "Structural and functional analysis of the middle segment of hsp90:
RT   implications for ATP hydrolysis and client protein and cochaperone
RT   interactions.";
RL   Mol. Cell 11:647-658(2003).
RN   [28] {ECO:0007744|PDB:1US7}
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-214 IN COMPLEX WITH HUMAN CDC37.
RX   PubMed=14718169; DOI=10.1016/s0092-8674(03)01027-4;
RA   Roe S.M., Ali M.M., Meyer P., Vaughan C.K., Panaretou B., Piper P.W.,
RA   Prodromou C., Pearl L.H.;
RT   "The Mechanism of Hsp90 regulation by the protein kinase-specific
RT   cochaperone p50(cdc37).";
RL   Cell 116:87-98(2004).
RN   [29] {ECO:0007744|PDB:1USU, ECO:0007744|PDB:1USV}
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 272-530 IN COMPLEX WITH AHA1, AND
RP   MUTAGENESIS OF LYS-387.
RX   PubMed=14739935; DOI=10.1038/sj.emboj.7600060;
RA   Meyer P.;
RT   "Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90
RT   chaperone machinery.";
RL   EMBO J. 23:511-519(2004).
RN   [30]
RP   ERRATUM OF PUBMED:14739935.
RX   PubMed=15039704; DOI=10.1038/sj.emboj.7600141;
RA   Meyer P., Prodromou C., Liao C., Hu B., Mark Roe S., Vaughan C.K.,
RA   Vlasic I., Panaretou B., Piper P.W., Pearl L.H.;
RL   EMBO J. 23:1402-1410(2004).
RN   [31]
RP   MUTAGENESIS OF ALA-577.
RX   PubMed=19696785; DOI=10.1038/embor.2009.153;
RA   Retzlaff M., Stahl M., Eberl H.C., Lagleder S., Beck J., Kessler H.,
RA   Buchner J.;
RT   "Hsp90 is regulated by a switch point in the C-terminal domain.";
RL   EMBO Rep. 10:1147-1153(2009).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1-214 IN COMPLEX WITH RADICICOL,
RP   AND ATPASE ACTIVITY.
RX   PubMed=9925731; DOI=10.1021/jm980403y;
RA   Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H.;
RT   "Structural basis for inhibition of the Hsp90 molecular chaperone by the
RT   antitumor antibiotics radicicol and geldanamycin.";
RL   J. Med. Chem. 42:260-266(1999).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1-214 IN COMPLEX WITH INHIBITORS,
RP   AND FUNCTION.
RX   PubMed=17114002; DOI=10.1016/j.chembiol.2006.09.015;
RA   Proisy N., Sharp S.Y., Boxall K., Connelly S., Roe S.M., Prodromou C.,
RA   Slawin A.M., Pearl L.H., Workman P., Moody C.J.;
RT   "Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural
RT   and biological evaluation of ring and conformational analogs of
RT   radicicol.";
RL   Chem. Biol. 13:1203-1215(2006).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 25-210, AND ATPASE ACTIVITY.
RX   PubMed=16461354; DOI=10.1074/jbc.m510142200;
RA   Richter K., Moser S., Hagn F., Friedrich R., Hainzl O., Heller M.,
RA   Schlee S., Kessler H., Reinstein J., Buchner J.;
RT   "Intrinsic inhibition of the Hsp90 ATPase activity.";
RL   J. Biol. Chem. 281:11301-11311(2006).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 1-677 IN COMPLEX WITH SBA1 AND
RP   ATP, AND SUBUNIT.
RX   PubMed=16625188; DOI=10.1038/nature04716;
RA   Ali M.M., Roe S.M., Vaughan C.K., Meyer P., Panaretou B., Piper P.W.,
RA   Prodromou C., Pearl L.H.;
RT   "Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone
RT   complex.";
RL   Nature 440:1013-1017(2006).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-219 IN COMPLEX WITH INHIBITOR,
RP   AND ATPASE ACTIVITY.
RX   PubMed=18357975; DOI=10.1021/jm701558c;
RA   Martin C.J., Gaisser S., Challis I.R., Carletti I., Wilkinson B.,
RA   Gregory M., Prodromou C., Roe S.M., Pearl L.H., Boyd S.M., Zhang M.Q.;
RT   "Molecular characterization of macbecin as an Hsp90 inhibitor.";
RL   J. Med. Chem. 51:2853-2857(2008).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1-220 IN COMPLEX WITH ADP;
RP   GELDANAMYCIN AND RADICICOL.
RX   PubMed=19236053; DOI=10.1021/cb9000316;
RA   Prodromou C., Nuttall J.M., Millson S.H., Roe S.M., Sim T.S., Tan D.,
RA   Workman P., Pearl L.H., Piper P.W.;
RT   "Structural basis of the radicicol resistance displayed by a fungal
RT   hsp90.";
RL   ACS Chem. Biol. 4:289-297(2009).
CC   -!- FUNCTION: Molecular chaperone that promotes the maturation, structural
CC       maintenance and proper regulation of specific target proteins involved
CC       in cell cycle control and signal transduction. Undergoes a functional
CC       cycle that is linked to its ATPase activity. The nucleotide-free form
CC       of the dimer is found in an open conformation in which the N-termini
CC       are not dimerized and the complex is ready for client protein binding.
CC       Binding of ATP induces large conformational changes, resulting in the
CC       formation of a ring-like closed structure in which the N-terminal
CC       domains associate intramolecularly with the middle domain and also
CC       dimerize with each other, stimulating their intrinsic ATPase activity
CC       and acting as a clamp on the substrate. Finally, ATP hydrolysis results
CC       in the release of the substrate. This cycle probably induces
CC       conformational changes in the client proteins, thereby causing their
CC       activation. Interacts dynamically with various co-chaperones that
CC       modulate its substrate recognition, ATPase cycle and chaperone
CC       function. Required for growth at high temperatures.
CC       {ECO:0000269|PubMed:17114002}.
CC   -!- ACTIVITY REGULATION: Inhibited by geldanamycin, macbecin I and
CC       radicicol, which bind to the ATP-binding pocket. Co-chaperones CDC37,
CC       SBA1 and STI1 reduce ATPase activity. Co-chaperones AHA1 and HCH1
CC       increase ATPase activity.
CC   -!- SUBUNIT: Homodimer. Interacts with the co-chaperones AHA1, CDC37, CNS1,
CC       CPR6, CPR7, HCH1, SBA1, SSE1 and STI1. CNS1, CPR6, CPR7 and STI1.
CC       Interacts directly with the substrates GCN2, HAP1 and STE11.
CC       {ECO:0000269|PubMed:10480867, ECO:0000269|PubMed:10567567,
CC       ECO:0000269|PubMed:10664467, ECO:0000269|PubMed:12504007,
CC       ECO:0000269|PubMed:14718169, ECO:0000269|PubMed:14739935,
CC       ECO:0000269|PubMed:16625188, ECO:0000269|PubMed:17114002,
CC       ECO:0000269|PubMed:18357975, ECO:0000269|PubMed:19236053,
CC       ECO:0000269|PubMed:7929182, ECO:0000269|PubMed:8939862,
CC       ECO:0000269|PubMed:9230303, ECO:0000269|PubMed:9632755,
CC       ECO:0000269|PubMed:9632766, ECO:0000269|PubMed:9817749,
CC       ECO:0000269|PubMed:9819421, ECO:0000269|PubMed:9925731}.
CC   -!- INTERACTION:
CC       P02829; P60010: ACT1; NbExp=2; IntAct=EBI-8659, EBI-2169;
CC       P02829; P27616: ADE1; NbExp=2; IntAct=EBI-8659, EBI-14257;
CC       P02829; Q12449: AHA1; NbExp=15; IntAct=EBI-8659, EBI-37072;
CC       P02829; P46672: ARC1; NbExp=2; IntAct=EBI-8659, EBI-7224;
CC       P02829; P00830: ATP2; NbExp=2; IntAct=EBI-8659, EBI-3242;
CC       P02829; P53858: BNI4; NbExp=2; IntAct=EBI-8659, EBI-3704;
CC       P02829; P33322: CBF5; NbExp=4; IntAct=EBI-8659, EBI-4105;
CC       P02829; P06101: CDC37; NbExp=6; IntAct=EBI-8659, EBI-4266;
CC       P02829; Q12102: CFT2; NbExp=2; IntAct=EBI-8659, EBI-31412;
CC       P02829; P33313: CNS1; NbExp=7; IntAct=EBI-8659, EBI-4806;
CC       P02829; P53691: CPR6; NbExp=27; IntAct=EBI-8659, EBI-5429;
CC       P02829; P47103: CPR7; NbExp=6; IntAct=EBI-8659, EBI-5436;
CC       P02829; Q01454: CTF4; NbExp=2; IntAct=EBI-8659, EBI-5209;
CC       P02829; P38241: ECM2; NbExp=4; IntAct=EBI-8659, EBI-780;
CC       P02829; P53743: ESF2; NbExp=2; IntAct=EBI-8659, EBI-28537;
CC       P02829; P38866: FMO1; NbExp=3; IntAct=EBI-8659, EBI-24830;
CC       P02829; Q07825: FRA1; NbExp=2; IntAct=EBI-8659, EBI-32387;
CC       P02829; P15442: GCN2; NbExp=3; IntAct=EBI-8659, EBI-330;
CC       P02829; P53834: HCH1; NbExp=2; IntAct=EBI-8659, EBI-28288;
CC       P02829; Q12276: HER1; NbExp=2; IntAct=EBI-8659, EBI-35056;
CC       P02829; Q08109: HRD1; NbExp=3; IntAct=EBI-8659, EBI-37613;
CC       P02829; P15108: HSC82; NbExp=46; IntAct=EBI-8659, EBI-8666;
CC       P02829; P02829: HSP82; NbExp=11; IntAct=EBI-8659, EBI-8659;
CC       P02829; P43581: HXT10; NbExp=2; IntAct=EBI-8659, EBI-8750;
CC       P02829; P38828: LSM12; NbExp=3; IntAct=EBI-8659, EBI-24700;
CC       P02829; P39534: MBB1; NbExp=2; IntAct=EBI-8659, EBI-26211;
CC       P02829; P27705: MIG1; NbExp=3; IntAct=EBI-8659, EBI-10913;
CC       P02829; P33759: MRPS5; NbExp=12; IntAct=EBI-8659, EBI-413;
CC       P02829; P35198: MTH1; NbExp=3; IntAct=EBI-8659, EBI-11561;
CC       P02829; P32832: NPL6; NbExp=2; IntAct=EBI-8659, EBI-12202;
CC       P02829; P38264: PHO88; NbExp=2; IntAct=EBI-8659, EBI-13350;
CC       P02829; P38768: PIH1; NbExp=5; IntAct=EBI-8659, EBI-24499;
CC       P02829; Q03407: PKH1; NbExp=2; IntAct=EBI-8659, EBI-32467;
CC       P02829; P53043: PPT1; NbExp=14; IntAct=EBI-8659, EBI-13796;
CC       P02829; P32264: PRO1; NbExp=3; IntAct=EBI-8659, EBI-13879;
CC       P02829; P25635: PWP2; NbExp=2; IntAct=EBI-8659, EBI-14332;
CC       P02829; P38764: RPN1; NbExp=2; IntAct=EBI-8659, EBI-15913;
CC       P02829; P28707: SBA1; NbExp=7; IntAct=EBI-8659, EBI-26838;
CC       P02829; P41811: SEC27; NbExp=2; IntAct=EBI-8659, EBI-4898;
CC       P02829; Q08446: SGT1; NbExp=2; IntAct=EBI-8659, EBI-17070;
CC       P02829; P17883: SKI3; NbExp=2; IntAct=EBI-8659, EBI-1861;
CC       P02829; Q00772: SLT2; NbExp=5; IntAct=EBI-8659, EBI-17372;
CC       P02829; P41808: SMK1; NbExp=4; IntAct=EBI-8659, EBI-17457;
CC       P02829; P10591: SSA1; NbExp=5; IntAct=EBI-8659, EBI-8591;
CC       P02829; P10592: SSA2; NbExp=4; IntAct=EBI-8659, EBI-8603;
CC       P02829; P11484: SSB1; NbExp=3; IntAct=EBI-8659, EBI-8627;
CC       P02829; P32589: SSE1; NbExp=5; IntAct=EBI-8659, EBI-8648;
CC       P02829; P53599: SSK2; NbExp=2; IntAct=EBI-8659, EBI-18191;
CC       P02829; P38788: SSZ1; NbExp=3; IntAct=EBI-8659, EBI-24570;
CC       P02829; P15705: STI1; NbExp=44; IntAct=EBI-8659, EBI-18418;
CC       P02829; P38129: TAF5; NbExp=3; IntAct=EBI-8659, EBI-18868;
CC       P02829; P25638: TAH1; NbExp=11; IntAct=EBI-8659, EBI-21956;
CC       P02829; P00359: TDH3; NbExp=2; IntAct=EBI-8659, EBI-7218;
CC       P02829; P10081: TIF2; NbExp=3; IntAct=EBI-8659, EBI-9017;
CC       P02829; P53874: UBP10; NbExp=2; IntAct=EBI-8659, EBI-19873;
CC       P02829; P25491: YDJ1; NbExp=3; IntAct=EBI-8659, EBI-10420;
CC       P02829; Q12407: YDL199C; NbExp=3; IntAct=EBI-8659, EBI-33162;
CC       P02829; P38887: YHR202W; NbExp=2; IntAct=EBI-8659, EBI-24252;
CC       P02829; P38746: YLF2; NbExp=2; IntAct=EBI-8659, EBI-27201;
CC       P02829; Q06224: YSH1; NbExp=2; IntAct=EBI-8659, EBI-38345;
CC       P02829; P0CS82: HAP1; Xeno; NbExp=4; IntAct=EBI-8659, EBI-5419;
CC       P02829; P04637: TP53; Xeno; NbExp=8; IntAct=EBI-8659, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14562095}.
CC   -!- INDUCTION: Expressed constitutively and induced by high temperatures
CC       dependent on transcription factor HSF1. According to PubMed:2674684, it
CC       is constitutively expressed at low levels, however, due to the
CC       specificity of the antibody, this result is unsure.
CC       {ECO:0000269|PubMed:2674684, ECO:0000269|PubMed:9296388}.
CC   -!- DOMAIN: The TPR repeat-binding motif mediates interaction with TPR
CC       repeat-containing proteins like the co-chaperones AHA1, CDC37, CNS1,
CC       CPR6, CPR7, HCH1, SBA1, SSE1 and STI1. CNS1, CPR6, CPR7 and STI1.
CC   -!- MISCELLANEOUS: Present with 444943 molecules/cell in log phase SD
CC       medium. {ECO:0000269|PubMed:14562106}.
CC   -!- SIMILARITY: Belongs to the heat shock protein 90 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; K01387; AAA02743.1; -; Unassigned_RNA.
DR   EMBL; Z67751; CAA91604.1; -; Genomic_DNA.
DR   EMBL; Z73596; CAA97961.1; -; Genomic_DNA.
DR   EMBL; BK006949; DAA11197.1; -; Genomic_DNA.
DR   PIR; A03313; HHBY90.
DR   RefSeq; NP_015084.1; NM_001184054.1.
DR   PDB; 1A4H; X-ray; 2.50 A; A=1-220.
DR   PDB; 1AH6; X-ray; 1.80 A; A=1-220.
DR   PDB; 1AH8; X-ray; 2.10 A; A/B=1-220.
DR   PDB; 1AM1; X-ray; 2.00 A; A=2-214.
DR   PDB; 1AMW; X-ray; 1.85 A; A=1-214.
DR   PDB; 1BGQ; X-ray; 2.50 A; A=1-214.
DR   PDB; 1HK7; X-ray; 2.50 A; A/B=273-560.
DR   PDB; 1US7; X-ray; 2.30 A; A=1-214.
DR   PDB; 1USU; X-ray; 2.15 A; A=273-530.
DR   PDB; 1USV; X-ray; 2.70 A; A/C/E/G=272-530.
DR   PDB; 1ZW9; X-ray; 1.90 A; A=1-220.
DR   PDB; 1ZWH; X-ray; 1.65 A; A=1-220.
DR   PDB; 2AKP; X-ray; 1.94 A; A/B=25-210.
DR   PDB; 2BRC; X-ray; 1.60 A; A=1-214.
DR   PDB; 2BRE; X-ray; 2.00 A; A/B=1-219.
DR   PDB; 2CG9; X-ray; 3.10 A; A/B=1-677.
DR   PDB; 2CGE; X-ray; 3.00 A; A/B/D=273-677.
DR   PDB; 2CGF; X-ray; 2.20 A; A=1-214.
DR   PDB; 2FXS; X-ray; 2.00 A; A=1-220.
DR   PDB; 2IWS; X-ray; 2.70 A; A=1-214.
DR   PDB; 2IWU; X-ray; 2.80 A; A=1-214.
DR   PDB; 2IWX; X-ray; 1.50 A; A=1-214.
DR   PDB; 2LSV; NMR; -; B=701-709.
DR   PDB; 2VW5; X-ray; 1.90 A; A/B/C/D=1-214.
DR   PDB; 2VWC; X-ray; 2.40 A; A=1-219.
DR   PDB; 2WEP; X-ray; 2.00 A; A=1-220.
DR   PDB; 2WEQ; X-ray; 2.20 A; A=1-220.
DR   PDB; 2WER; X-ray; 1.60 A; A/B=1-220.
DR   PDB; 2XD6; X-ray; 2.20 A; A=1-214.
DR   PDB; 2XX2; X-ray; 1.85 A; A/B/C/D=1-214.
DR   PDB; 2XX4; X-ray; 2.20 A; A=1-214.
DR   PDB; 2XX5; X-ray; 2.00 A; A=1-214.
DR   PDB; 2YGA; X-ray; 2.37 A; A=1-220.
DR   PDB; 2YGE; X-ray; 1.96 A; A=1-220.
DR   PDB; 2YGF; X-ray; 2.00 A; A=1-220.
DR   PDB; 3C0E; X-ray; 1.90 A; A=1-220.
DR   PDB; 3C11; X-ray; 1.60 A; A=1-220.
DR   PDB; 3FP2; X-ray; 1.98 A; Q=698-709.
DR   PDB; 4AS9; X-ray; 2.71 A; A=1-220.
DR   PDB; 4ASA; X-ray; 2.25 A; A=1-220.
DR   PDB; 4ASB; X-ray; 3.08 A; A=1-220.
DR   PDB; 4ASF; X-ray; 2.60 A; A=1-220.
DR   PDB; 4ASG; X-ray; 2.20 A; A=1-220.
DR   PDB; 4CE1; X-ray; 2.01 A; A=1-214.
DR   PDB; 4CE2; X-ray; 2.38 A; A=1-214.
DR   PDB; 4CE3; X-ray; 2.31 A; A=1-214.
DR   PDB; 5MGX; X-ray; 2.18 A; A/B/C/D=702-709.
DR   PDB; 8OXU; X-ray; 2.94 A; A/B/C/D=439-679.
DR   PDBsum; 1A4H; -.
DR   PDBsum; 1AH6; -.
DR   PDBsum; 1AH8; -.
DR   PDBsum; 1AM1; -.
DR   PDBsum; 1AMW; -.
DR   PDBsum; 1BGQ; -.
DR   PDBsum; 1HK7; -.
DR   PDBsum; 1US7; -.
DR   PDBsum; 1USU; -.
DR   PDBsum; 1USV; -.
DR   PDBsum; 1ZW9; -.
DR   PDBsum; 1ZWH; -.
DR   PDBsum; 2AKP; -.
DR   PDBsum; 2BRC; -.
DR   PDBsum; 2BRE; -.
DR   PDBsum; 2CG9; -.
DR   PDBsum; 2CGE; -.
DR   PDBsum; 2CGF; -.
DR   PDBsum; 2FXS; -.
DR   PDBsum; 2IWS; -.
DR   PDBsum; 2IWU; -.
DR   PDBsum; 2IWX; -.
DR   PDBsum; 2LSV; -.
DR   PDBsum; 2VW5; -.
DR   PDBsum; 2VWC; -.
DR   PDBsum; 2WEP; -.
DR   PDBsum; 2WEQ; -.
DR   PDBsum; 2WER; -.
DR   PDBsum; 2XD6; -.
DR   PDBsum; 2XX2; -.
DR   PDBsum; 2XX4; -.
DR   PDBsum; 2XX5; -.
DR   PDBsum; 2YGA; -.
DR   PDBsum; 2YGE; -.
DR   PDBsum; 2YGF; -.
DR   PDBsum; 3C0E; -.
DR   PDBsum; 3C11; -.
DR   PDBsum; 3FP2; -.
DR   PDBsum; 4AS9; -.
DR   PDBsum; 4ASA; -.
DR   PDBsum; 4ASB; -.
DR   PDBsum; 4ASF; -.
DR   PDBsum; 4ASG; -.
DR   PDBsum; 4CE1; -.
DR   PDBsum; 4CE2; -.
DR   PDBsum; 4CE3; -.
DR   PDBsum; 5MGX; -.
DR   PDBsum; 8OXU; -.
DR   AlphaFoldDB; P02829; -.
DR   BMRB; P02829; -.
DR   SMR; P02829; -.
DR   BioGRID; 35923; 1886.
DR   ComplexPortal; CPX-1276; HMC complex.
DR   DIP; DIP-2262N; -.
DR   FunCoup; P02829; 1767.
DR   IntAct; P02829; 1189.
DR   MINT; P02829; -.
DR   STRING; 4932.YPL240C; -.
DR   BindingDB; P02829; -.
DR   ChEMBL; CHEMBL3536; -.
DR   DrugCentral; P02829; -.
DR   iPTMnet; P02829; -.
DR   PaxDb; 4932-YPL240C; -.
DR   PeptideAtlas; P02829; -.
DR   EnsemblFungi; YPL240C_mRNA; YPL240C; YPL240C.
DR   GeneID; 855836; -.
DR   KEGG; sce:YPL240C; -.
DR   AGR; SGD:S000006161; -.
DR   SGD; S000006161; HSP82.
DR   VEuPathDB; FungiDB:YPL240C; -.
DR   eggNOG; KOG0019; Eukaryota.
DR   HOGENOM; CLU_006684_1_3_1; -.
DR   InParanoid; P02829; -.
DR   OMA; MRRMKEM; -.
DR   OrthoDB; 28737at2759; -.
DR   BioCyc; YEAST:G3O-34126-MONOMER; -.
DR   BRENDA; 3.6.4.10; 984.
DR   Reactome; R-SCE-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
DR   Reactome; R-SCE-203615; eNOS activation.
DR   Reactome; R-SCE-3371497; HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand.
DR   Reactome; R-SCE-3371511; HSF1 activation.
DR   Reactome; R-SCE-3371571; HSF1-dependent transactivation.
DR   Reactome; R-SCE-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-SCE-6798695; Neutrophil degranulation.
DR   Reactome; R-SCE-844456; The NLRP3 inflammasome.
DR   Reactome; R-SCE-9009391; Extra-nuclear estrogen signaling.
DR   SABIO-RK; P02829; -.
DR   BioGRID-ORCS; 855836; 0 hits in 10 CRISPR screens.
DR   EvolutionaryTrace; P02829; -.
DR   PHI-base; PHI:463; -.
DR   PRO; PR:P02829; -.
DR   Proteomes; UP000002311; Chromosome XVI.
DR   RNAct; P02829; protein.
DR   GO; GO:0005737; C:cytoplasm; IDA:SGD.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:SGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0032991; C:protein-containing complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IBA:GO_Central.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:SGD.
DR   GO; GO:0140662; F:ATP-dependent protein folding chaperone; IEA:InterPro.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051082; F:unfolded protein binding; IDA:SGD.
DR   GO; GO:0006458; P:'de novo' protein folding; IDA:SGD.
DR   GO; GO:0000492; P:box C/D snoRNP assembly; IMP:SGD.
DR   GO; GO:0034605; P:cellular response to heat; IBA:GO_Central.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IDA:SGD.
DR   GO; GO:0043248; P:proteasome assembly; IDA:SGD.
DR   GO; GO:0006457; P:protein folding; IBA:GO_Central.
DR   GO; GO:0051604; P:protein maturation; IMP:SGD.
DR   GO; GO:0042026; P:protein refolding; IMP:SGD.
DR   GO; GO:0050821; P:protein stabilization; IBA:GO_Central.
DR   GO; GO:0006626; P:protein targeting to mitochondrion; IPI:SGD.
DR   GO; GO:0032204; P:regulation of telomere maintenance; IMP:CACAO.
DR   GO; GO:0006970; P:response to osmotic stress; IMP:SGD.
DR   GO; GO:0070482; P:response to oxygen levels; NAS:ComplexPortal.
DR   CDD; cd16927; HATPase_Hsp90-like; 1.
DR   FunFam; 1.20.120.790:FF:000001; Heat shock protein 90 alpha; 1.
DR   FunFam; 3.30.230.80:FF:000001; Heat shock protein 90 alpha; 1.
DR   FunFam; 3.40.50.11260:FF:000001; Heat shock protein 90 alpha; 1.
DR   FunFam; 3.30.565.10:FF:000001; Heat shock protein HSP 90-alpha; 1.
DR   Gene3D; 3.30.230.80; -; 1.
DR   Gene3D; 3.40.50.11260; -; 1.
DR   Gene3D; 1.20.120.790; Heat shock protein 90, C-terminal domain; 1.
DR   Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1.
DR   HAMAP; MF_00505; HSP90; 1.
DR   InterPro; IPR036890; HATPase_C_sf.
DR   InterPro; IPR003594; HATPase_dom.
DR   InterPro; IPR019805; Heat_shock_protein_90_CS.
DR   InterPro; IPR037196; HSP90_C.
DR   InterPro; IPR001404; Hsp90_fam.
DR   InterPro; IPR020575; Hsp90_N.
DR   InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF.
DR   NCBIfam; NF003555; PRK05218.1; 1.
DR   PANTHER; PTHR11528; HEAT SHOCK PROTEIN 90 FAMILY MEMBER; 1.
DR   Pfam; PF13589; HATPase_c_3; 1.
DR   Pfam; PF00183; HSP90; 1.
DR   PIRSF; PIRSF002583; Hsp90; 1.
DR   PRINTS; PR00775; HEATSHOCK90.
DR   SMART; SM00387; HATPase_c; 1.
DR   SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1.
DR   SUPFAM; SSF110942; HSP90 C-terminal domain; 1.
DR   SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1.
DR   PROSITE; PS00298; HSP90; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Chaperone; Cytoplasm; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Repeat; Stress response.
FT   CHAIN           1..709
FT                   /note="ATP-dependent molecular chaperone HSP82"
FT                   /id="PRO_0000062957"
FT   REPEAT          221..225
FT                   /note="1"
FT                   /evidence="ECO:0000269|PubMed:10786835"
FT   REPEAT          226..230
FT                   /note="2"
FT                   /evidence="ECO:0000269|PubMed:10786835"
FT   REPEAT          231..235
FT                   /note="3"
FT                   /evidence="ECO:0000269|PubMed:10786835"
FT   REPEAT          237..241
FT                   /note="4"
FT                   /evidence="ECO:0000269|PubMed:10786835"
FT   REPEAT          250..254
FT                   /note="5"
FT                   /evidence="ECO:0000269|PubMed:10786835"
FT   REGION          219..262
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          221..263
FT                   /note="5 X 5 AA repeats of [DE]-[DE]-[DE]-K-K; highly
FT                   charged region"
FT   REGION          679..709
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           705..709
FT                   /note="TPR repeat-binding"
FT   COMPBIAS        219..245
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        687..698
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        699..709
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         33
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0007744|PDB:2CG9"
FT   BINDING         37
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0000269|PubMed:9230303, ECO:0007744|PDB:1AM1,
FT                   ECO:0007744|PDB:1AMW, ECO:0007744|PDB:2CG9,
FT                   ECO:0007744|PDB:2WEP"
FT   BINDING         79
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0000269|PubMed:9230303, ECO:0007744|PDB:1AM1,
FT                   ECO:0007744|PDB:1AMW, ECO:0007744|PDB:2CG9,
FT                   ECO:0007744|PDB:2WEP"
FT   BINDING         84
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0007744|PDB:2CG9"
FT   BINDING         92
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0007744|PDB:2CG9"
FT   BINDING         98
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0007744|PDB:2CG9"
FT   BINDING         99..100
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0007744|PDB:2CG9"
FT   BINDING         119..124
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0000269|PubMed:9230303, ECO:0007744|PDB:1AM1,
FT                   ECO:0007744|PDB:1AMW, ECO:0007744|PDB:2CG9,
FT                   ECO:0007744|PDB:2WEP"
FT   BINDING         171
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0007744|PDB:2CG9"
FT   BINDING         380
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16625188,
FT                   ECO:0007744|PDB:2CG9"
FT   MOD_RES         657
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P15108"
FT   MUTAGEN         22
FT                   /note="T->I: Induces a 6-fold increase in ATPase activity
FT                   and a reduced client protein activation activity, leading
FT                   to growth defect at high temperatures."
FT                   /evidence="ECO:0000269|PubMed:7791797"
FT   MUTAGEN         41
FT                   /note="A->V: Causes a 98% reduction in ATPase activity and
FT                   a reduced client protein activation activity, leading to
FT                   growth defect at high temperatures."
FT                   /evidence="ECO:0000269|PubMed:7791797"
FT   MUTAGEN         81
FT                   /note="G->S: Reduces client protein activation activity,
FT                   leading to growth defect at high temperatures."
FT                   /evidence="ECO:0000269|PubMed:7791797"
FT   MUTAGEN         83
FT                   /note="G->D: Abolishes ATPase activity."
FT                   /evidence="ECO:0000269|PubMed:18256191"
FT   MUTAGEN         97
FT                   /note="A->I: Abolishes interaction with SBA1."
FT                   /evidence="ECO:0000269|PubMed:9632755"
FT   MUTAGEN         101
FT                   /note="T->I: Causes a 90% reduction in ATPase activity and
FT                   a reduced client protein activation activity, leading to
FT                   growth defect at high temperatures."
FT                   /evidence="ECO:0000269|PubMed:7791797"
FT   MUTAGEN         107
FT                   /note="A->N: Induces a 6-fold increase in ATPase activity."
FT                   /evidence="ECO:0000269|PubMed:10944121"
FT   MUTAGEN         170
FT                   /note="G->D: Induces a total loss of function at 34 degrees
FT                   Celsius. Abolishes interaction with SBA1."
FT                   /evidence="ECO:0000269|PubMed:7791797"
FT   MUTAGEN         313
FT                   /note="G->N,S: Reduces client protein activation activity,
FT                   leading to growth defect at high temperatures."
FT                   /evidence="ECO:0000269|PubMed:7791797,
FT                   ECO:0000269|PubMed:8248264"
FT   MUTAGEN         349
FT                   /note="F->A,Q: Induces a loss of ATPase activity. Can be
FT                   reactivated by AHA1."
FT                   /evidence="ECO:0000269|PubMed:12667448"
FT   MUTAGEN         380
FT                   /note="R->A: Induces a loss of ATPase activity."
FT                   /evidence="ECO:0000269|PubMed:12667448"
FT   MUTAGEN         381
FT                   /note="E->K: Reduces client protein activation activity.
FT                   Resistant to ATPase activation by AHA1."
FT                   /evidence="ECO:0000269|PubMed:7791797"
FT   MUTAGEN         384
FT                   /note="Q->A: Induces a loss of ATPase activity."
FT                   /evidence="ECO:0000269|PubMed:12667448"
FT   MUTAGEN         387
FT                   /note="K->A: Decreases AHA1 binding affinity, but has no
FT                   effect on client protein activation activity."
FT                   /evidence="ECO:0000269|PubMed:14739935"
FT   MUTAGEN         387
FT                   /note="K->D: Decreases AHA1 binding affinity and
FT                   substantially reduces client protein activation activity."
FT                   /evidence="ECO:0000269|PubMed:14739935"
FT   MUTAGEN         431
FT                   /note="E->K: Specifically reduces the activation of the
FT                   exogenous ligand glucocorticoid receptor."
FT                   /evidence="ECO:0000269|PubMed:8248264"
FT   MUTAGEN         485
FT                   /note="S->Y: Abolishes interaction with SBA1."
FT                   /evidence="ECO:0000269|PubMed:9632755"
FT   MUTAGEN         525
FT                   /note="T->I: Abolishes interaction with SBA1. Reduces
FT                   client protein activation activity, leading to growth
FT                   defect at high temperatures."
FT                   /evidence="ECO:0000269|PubMed:8248264"
FT   MUTAGEN         576
FT                   /note="A->T: Reduces client protein activation activity;
FT                   when associated with K-579."
FT                   /evidence="ECO:0000269|PubMed:8248264"
FT   MUTAGEN         577
FT                   /note="A->C: Enhances ATPase activity and client protein
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:19696785"
FT   MUTAGEN         577
FT                   /note="A->D: Reduces ATPase activity and client protein
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:19696785"
FT   MUTAGEN         577
FT                   /note="A->I: Enhances homodimerization, ATPase activity and
FT                   client protein activation."
FT                   /evidence="ECO:0000269|PubMed:19696785"
FT   MUTAGEN         577
FT                   /note="A->N: Reduces homodimerization, ATPase activity and
FT                   client protein activation."
FT                   /evidence="ECO:0000269|PubMed:19696785"
FT   MUTAGEN         579
FT                   /note="R->K: Reduces client protein activation activity;
FT                   when associated with T-576."
FT                   /evidence="ECO:0000269|PubMed:8248264"
FT   MUTAGEN         587
FT                   /note="A->T: No effect on ATPase activity. Reduces client
FT                   protein activation activity, leading to growth defect at
FT                   high temperatures."
FT                   /evidence="ECO:0000269|PubMed:7791797"
FT   CONFLICT        481
FT                   /note="A -> S (in Ref. 27)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..7
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           10..21
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           26..28
FT                   /evidence="ECO:0007829|PDB:4ASB"
FT   HELIX           29..48
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   TURN            49..51
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           53..56
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   STRAND          64..69
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           70..72
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   STRAND          74..79
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           86..93
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   TURN            95..97
FT                   /evidence="ECO:0007829|PDB:2BRC"
FT   HELIX           101..110
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           114..120
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           123..129
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   STRAND          131..139
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   STRAND          146..150
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   STRAND          152..160
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   STRAND          162..164
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   STRAND          168..177
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           182..185
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           187..197
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   STRAND          200..203
FT                   /evidence="ECO:0007829|PDB:2AKP"
FT   STRAND          205..207
FT                   /evidence="ECO:0007829|PDB:2IWX"
FT   HELIX           276..278
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   HELIX           281..283
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   HELIX           286..297
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          304..311
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          313..315
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          317..323
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   TURN            329..332
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          335..337
FT                   /evidence="ECO:0007829|PDB:2CG9"
FT   STRAND          341..345
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          348..352
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          355..358
FT                   /evidence="ECO:0007829|PDB:1HK7"
FT   HELIX           360..362
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          366..373
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   HELIX           380..383
FT                   /evidence="ECO:0007829|PDB:1HK7"
FT   HELIX           387..408
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   HELIX           411..431
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   TURN            433..435
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   HELIX           436..440
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          444..447
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          450..456
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   HELIX           457..462
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          470..475
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   HELIX           479..483
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   HELIX           488..493
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          498..501
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   HELIX           504..513
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   STRAND          519..523
FT                   /evidence="ECO:0007829|PDB:1USU"
FT   TURN            524..526
FT                   /evidence="ECO:0007829|PDB:1HK7"
FT   STRAND          530..533
FT                   /evidence="ECO:0007829|PDB:2CGE"
FT   HELIX           536..546
FT                   /evidence="ECO:0007829|PDB:8OXU"
FT   HELIX           548..558
FT                   /evidence="ECO:0007829|PDB:8OXU"
FT   HELIX           559..561
FT                   /evidence="ECO:0007829|PDB:8OXU"
FT   STRAND          563..567
FT                   /evidence="ECO:0007829|PDB:8OXU"
FT   STRAND          573..580
FT                   /evidence="ECO:0007829|PDB:8OXU"
FT   STRAND          582..584
FT                   /evidence="ECO:0007829|PDB:2CGE"
FT   HELIX           587..595
FT                   /evidence="ECO:0007829|PDB:8OXU"
FT   STRAND          600..602
FT                   /evidence="ECO:0007829|PDB:2CGE"
FT   STRAND          611..615
FT                   /evidence="ECO:0007829|PDB:8OXU"
FT   HELIX           620..630
FT                   /evidence="ECO:0007829|PDB:8OXU"
FT   HELIX           633..635
FT                   /evidence="ECO:0007829|PDB:2CGE"
FT   HELIX           637..653
FT                   /evidence="ECO:0007829|PDB:8OXU"
FT   HELIX           661..674
FT                   /evidence="ECO:0007829|PDB:8OXU"
SQ   SEQUENCE   709 AA;  81406 MW;  D7C35676D668FB63 CRC64;
     MASETFEFQA EITQLMSLII NTVYSNKEIF LRELISNASD ALDKIRYKSL SDPKQLETEP
     DLFIRITPKP EQKVLEIRDS GIGMTKAELI NNLGTIAKSG TKAFMEALSA GADVSMIGQF
     GVGFYSLFLV ADRVQVISKS NDDEQYIWES NAGGSFTVTL DEVNERIGRG TILRLFLKDD
     QLEYLEEKRI KEVIKRHSEF VAYPIQLVVT KEVEKEVPIP EEEKKDEEKK DEEKKDEDDK
     KPKLEEVDEE EEKKPKTKKV KEEVQEIEEL NKTKPLWTRN PSDITQEEYN AFYKSISNDW
     EDPLYVKHFS VEGQLEFRAI LFIPKRAPFD LFESKKKKNN IKLYVRRVFI TDEAEDLIPE
     WLSFVKGVVD SEDLPLNLSR EMLQQNKIMK VIRKNIVKKL IEAFNEIAED SEQFEKFYSA
     FSKNIKLGVH EDTQNRAALA KLLRYNSTKS VDELTSLTDY VTRMPEHQKN IYYITGESLK
     AVEKSPFLDA LKAKNFEVLF LTDPIDEYAF TQLKEFEGKT LVDITKDFEL EETDEEKAER
     EKEIKEYEPL TKALKEILGD QVEKVVVSYK LLDAPAAIRT GQFGWSANME RIMKAQALRD
     SSMSSYMSSK KTFEISPKSP IIKELKKRVD EGGAQDKTVK DLTKLLYETA LLTSGFSLDE
     PTSFASRINR LISLGLNIDE DEETETAPEA STAAPVEEVP ADTEMEEVD
//
